Immuron Limited Sponsored ADRImmuron Limited Sponsored ADRImmuron Limited Sponsored ADR

Immuron Limited Sponsored ADR

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪13.48 M‬USD
−0.58USD
‪−3.38 M‬USD
‪4.72 M‬USD
Beta (1Y)
−0.32

About Immuron Limited


CEO
Steven Lydeamore
Headquarters
Blackburn
Founded
1994
ISIN
US45254U1016
FIGI
BBG000LZD9X8
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Check out other big names from the same industry as IMRN.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.